| [1] |
Xiao M, Sun ZY, Kang M, et al. Five-year national surveillance of invasive candidiasis: species distribution and azole susceptibility from the China hospital invasive fungal surveillance net (CHIF-NET) study[J]. J Clin Microbiol, 2018, 56(7): e00577-18. doi:10.1128/jcm.00577-18
|
| [2] |
Xiao M, Chen SC, Kong FR, et al. Distribution and antifungal susceptibility of Candida Species causing candidemia in China: an update from the CHIF-NET study[J]. J Infect Dis, 2020, 221(): S139-47. doi:10.1093/infdis/jiz573
|
| [3] |
Fan X, Xiao M, Liao K, et al. Notable increasing trend in azole non-susceptible Candida tropicalis causing invasive candidiasis in China (August 2009 to July 2014): molecular epidemiology and clinical azole consumption[J]. Front Microbiol, 2017, 8: 464. doi:10.3389/fmicb.2017.00464
|
| [4] |
Hou J, Deng J, Liu Y, et al. Epidemiology, clinical characteristics, risk factors, and outcomes of candidemia in a large tertiary teaching hospital in western China: a retrospective 5-year study from 2016 to 2020[J]. Antibiotics, 2022, 11(6): 788. doi:10.3390/antibiotics11060788
|
| [5] |
Xu H, Yu SY, Zhou ML, et al. Epidemiology and antifungal susceptibility patterns of invasive fungal infections from 2012 to 2014 in a teaching hospital in Central China[J]. Infect Drug Resist, 2019, 12: 3641-51. doi:10.2147/idr.s227839
|
| [6] |
Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study[J]. Clin Infect Dis, 2006, 43(1): 25-31. doi:10.1086/504810
|
| [7] |
Huang AM, Newton D, Kunapuli A, et al. Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia[J]. Clin Infect Dis, 2013, 57(9): 1237-45. doi:10.1093/cid/cit498
|
| [8] |
Knabl L, Lass-Flörl C. Antifungal susceptibility testing in Candida species: current methods and promising new tools for shortening the turnaround time[J]. Expert Rev Anti Infect Ther, 2020, 18(8): 779-87. doi:10.1080/14787210.2020.1760841
|
| [9] |
Durand C, Maubon D, Cornet M, et al. Can we improve antifungal susceptibility testing[J]? Front Cell Infect Microbiol, 2021, 11: 720609. doi:10.3389/fcimb.2021.720609
|
| [10] |
Marinach C, Alanio A, Palous M, et al. MALDI-TOF MS-based drug susceptibility testing of pathogens: The example of Candida albicans and fluconazole[J]. PROTEOMICS, 2009, 9(20): 4627-31. doi:10.1002/pmic.200900152
|
| [11] |
Delavy M, Cerutti L, Croxatto A, et al. Machine learning approach for Candida albicans fluconazole resistance detection using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry[J]. Front Microbiol, 2020, 10: 3000. doi:10.3389/fmicb.2019.03000
|
| [12] |
Vatanshenassan M, Arastehfar A, Boekhout T, et al. Anidulafungin susceptibility testing of Candida glabrata isolates from blood cultures by the MALDI biotyper antibiotic (antifungal) susceptibility test rapid assay[J]. Antimicrob Agents Chemother, 2019, 63(9): e00554-19. doi:10.1128/aac.00554-19
|
| [13] |
Paul S, Singh S, Chakrabarti A, et al. Stable isotope labelling: an approach for MALDI-TOF MS-based rapid detection of fluconazole resistance in Candida tropicalis [J]. J Antimicrob Chemother, 2019, 74(5): 1269-76. doi:10.1093/jac/dkz019
|
| [14] |
Vatanshenassan M, Boekhout T, Lass-Flörl C, et al. Proof of concept for MBT ASTRA, a rapid matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS)-based method to detect caspofungin resistance in Candida albicans and Candida glabrata[J]. J Clin Microbiol, 2018, 56(9): e00420-18. doi:10.1128/jcm.00420-18
|
| [15] |
Saracli MA, Fothergill AW, Sutton DA, et al. Detection of triazole resistance among Candida species by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS)[J]. Med Mycol, 2015, 53(7): 736-42. doi:10.1093/mmy/myv046
|
| [16] |
Paul S, Singh P, A S S, et al. Rapid detection of fluconazole resistance in Candida tropicalis by MALDI-TOF MS[J]. Med Mycol, 2018, 56(2): 234-41. doi:10.1093/mmy/myx042
|
| [17] |
CLSI. Performance Standards for Antifungal Susceptibility Testing of Yeasts: CLSI supplement M 27M44S,3rd ed . Wayne, PA: Clinical and Laboratory Standards Institute, 2022: 1-40
|
| [18] |
CLSI. Performance Standards for Antifungal Susceptibility Testing of Yeasts: CLSI supplement M60,1st ed . Wayne, PA: Clinical and Laboratory Standards Institute, 2017: 1-13.
|
| [19] |
Vella A, De Carolis E, Vaccaro L, et al. Rapid antifungal susceptibility testing by matrix-assisted laser desorption ionization-time of flight mass spectrometry analysis[J]. J Clin Microbiol, 2013, 51(9): 2964-9. doi:10.1128/jcm.00903-13
|
| [20] |
De Carolis E, Vella A, Florio AR, et al. Use of matrix-assisted laser desorption ionization-time of flight mass spectrometry for caspofungin susceptibility testing of Candida and Aspergillus species[J]. J Clin Microbiol, 2012, 50(7): 2479-83. doi:10.1128/jcm.00224-12
|
| [21] |
SENSITITRE YEASTONE For in vitro Diagnostic Use [Z]. 2012.
|
| [22] |
Cantón E, Pemán J, Hervás D, et al. Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and six Candida species as determined by the colorimetric sensititre YeastOne method[J]. J Clin Microbiol, 2012, 50(12): 3921-6. doi:10.1128/jcm.01730-12
|
| [23] |
Bertout S, Dunyach C, Drakulovski P, et al. Comparison of the Sensititre YeastOne® dilution method with the Clinical Laboratory Standards Institute (CLSI) M27-A3 microbroth dilution reference method for determining MIC of eight antifungal agents on 102 yeast strains[J]. Pathol Biol, 2011, 59(1): 48-51. doi:10.1016/j.patbio.2010.07.020
|
| [24] |
Alexander BD, Byrne TC, Smith KL, et al. Comparative evaluation of etest and sensititre YeastOne panels against the clinical and laboratory standards institute M27-A2 reference broth microdilution method for TestingCandidaSusceptibility to seven antifungal agents[J]. J Clin Microbiol, 2007, 45(3): 698-706. doi:10.1128/jcm.01840-06
|
| [25] |
Pfaller MA, Espinel-Ingroff A, Jones RN. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole[J]. J Clin Microbiol, 2004, 42(10): 4577-80. doi:10.1128/jcm.42.10.4577-4580.2004
|
| [26] |
Lombardi G, Farina C, Andreoni S, et al. Comparative evaluation of Sensititre® YeastOne vs. the NCCLS M27A protocol and E-test for antifungal susceptibility testing of yeasts[J]. Mycoses, 2004, 47(9/10): 397-401. doi:10.1111/j.1439-0507.2004.01013.x
|
| [27] |
Linares MJ, Charriel G, Solís F, et al. Comparison of two microdilution methods for testing susceptibility ofCandidaspp. to voriconazole[J]. J Clin Microbiol, 2004, 42(2): 899-902. doi:10.1128/jcm.42.2.899-902.2004
|
| [28] |
Espinel-Ingroff A, Pfaller M, Messer SA, et al. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp[J]. J Clin Microbiol, 2004, 42(2): 718-21. doi:10.1128/jcm.42.2.718-721.2004
|
| [29] |
Espinel-Ingroff A, Pfaller M, Messer SA, et al. Multicenter comparison of the sensititre YeastOne colorimetric antifungal panel with the national committee for clinical laboratory standards M27-a reference method for testing clinical isolates of common and EmergingCandidaspp., Cryptococcusspp., and other yeasts and yeast-like organisms[J]. J Clin Microbiol, 1999, 37(3): 591-5. doi:10.1128/jcm.37.3.591-595.1999
|
| [30] |
Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012[J]. J Clin Microbiol, 2012, 50(9): 2846-56. doi:10.1128/jcm.00937-12
|
| [31] |
Pfaller MA, Andes D, Diekema DJ, et al. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods[J]. Drug Resist Updat, 2010, 13(6): 180-95. doi:10.1016/j.drup.2010.09.002
|
| [32] |
Pfaller MA, Andes D, Arendrup MC, et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria[J]. Diagn Microbiol Infect Dis, 2011, 70(3): 330-43. doi:10.1016/j.diagmicrobio.2011.03.002
|
| [33] |
Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria[J]. Drug Resist Updat, 2011, 14(3): 164-76. doi:10.1016/j.drup.2011.01.004
|
| [34] |
Heuer C, Bahnemann J, Scheper T, et al. Paving the way to overcome antifungal drug resistance: current practices and novel developments for rapid and reliable antifungal susceptibility testing[J]. Small Meth, 2021, 5(11): 2100713. doi:10.1002/smtd.202100713
|
| [35] |
Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, et al. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities ofCandidaspp. to fluconazole, itraconazole, posaconazole, and voriconazole[J]. J Clin Microbiol, 2005, 43(8): 3884-9. doi:10.1128/jcm.43.8.3884-3889.2005
|
| [36] |
Vella A, De Carolis E, Mello E, et al. Potential use of MALDI-ToF mass spectrometry for rapid detection of antifungal resistance in the human pathogen Candida glabrata[J]. Sci Rep, 2017, 7: 9099. doi:10.1038/s41598-017-09329-4
|
| [37] |
Roberto AEM, Xavier DE, Vidal EE, et al. Rapid detection of echinocandins resistance by MALDI-TOF MS in Candida parapsilosis complex[J]. Microorganisms, 2020, 8(1): 109. doi:10.3390/microorganisms8010109
|
| [38] |
De Carolis E, Marchionni F, La Rosa M, et al. Are we ready for nosocomial Candida auris infections? rapid identification and antifungal resistance detection using MALDI-TOF mass spectrometry may be the answer[J]. Front Cell Infect Microbiol, 2021, 11: 645049. doi:10.3389/fcimb.2021.645049
|